Squarepoint Ops LLC Boosts Stake in Genmab A/S (NASDAQ:GMAB)

Squarepoint Ops LLC grew its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 1,235.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 117,507 shares of the company's stock after buying an additional 108,705 shares during the quarter. Squarepoint Ops LLC's holdings in Genmab A/S were worth $2,452,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the period. Barclays PLC grew its stake in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Cromwell Holdings LLC increased its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Genmab A/S in the 4th quarter valued at about $60,000. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Stock Performance

NASDAQ:GMAB traded down $0.39 during trading hours on Friday, reaching $20.93. The stock had a trading volume of 823,934 shares, compared to its average volume of 1,142,242. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $28.96. The company has a 50 day moving average price of $19.91 and a two-hundred day moving average price of $20.63. The stock has a market capitalization of $13.42 billion, a PE ratio of 12.03, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Equities research analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Truist Financial dropped their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Finally, Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.